Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Herald Sun
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
AsGGT2-F (5-CGAGCAAATTAATTCATTTTGGCTC AC-3) and AsGGT2-R (5-GCATACCAATCGCCACAAACTC-3) for AsGGT2
Shu S, Wang H, Zhu J et al (2022) Endoplasmic reticulum stress contributes to cisplatin-induced chronic kidney disease via the PERKPKC pathway
There is no universal dosage chart , which is why medical supervision is essential
US$ 25.69
US$ 29.92
US$ 22.36
